FY2025 · ended Dec 31, 2025 · Revenue $883.37M, +43.8% YoY · Filed Feb 27, 2026
Ani Pharmaceuticals, Inc (ANIP) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $883.4 million and net income of $78.3 million. Free cash flow was $171.4 million. As of Sep 30, 2026 it held $420.8 million in cash and investments and $297.7 million in total debt.
Revenue (TTM)
$1.04B
+25.9% vs year-ago TTM
Net income (TTM)
$116.84M
+188.0% vs year-ago TTM
Operating cash flow (TTM)
$229.20M
+34.3% vs year-ago TTM
Free cash flow (TTM)
$205.32M
+31.8% vs year-ago TTM
EPS (TTM)
$5.31
+219.5% vs year-ago TTM
Dividend per share
None
Shares outstanding
22.49M
Net cash
$123.08M
as of Sep 30, 2026
Operating margin
16.0%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ANIP (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Princeton, NJ
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1023024
- Former names
- BIOSANTE PHARMACEUTICALS INC (until Jul 18, 2013); BEN ABRAHAM TECHNOLOGIES INC (until Dec 23, 1999)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $883.4M | $614.4M | $486.8M | $316.4M | $216.1M |
| Operating income | $111.1M | $584,000 | $47.0M | -$35.3M | -$39.8M |
| Net income | $78.3M | -$18.5M | $18.8M | -$47.9M | -$42.6M |
| Diluted EPS | $3.32 | -$1.04 | $0.85 | -$3.05 | -$3.40 |
| Operating cash flow | $185.2M | $64.0M | $119.0M | -$31.2M | $3.3M |
| Free cash flow | $171.4M | $47.8M | $110.1M | -$40.1M | $765,000 |
| Total assets | $1.4B | $1.3B | $904.4M | $760.1M | $771.6M |
| Total liabilities | $899.7M | $855.9M | $446.8M | $421.5M | $412.9M |
| Stockholders' equity | $540.7M | $403.7M | $432.7M | $313.7M | $333.9M |
| Cash and investments | $285.6M | $144.9M | $221.1M | $48.2M | $100.3M |
| Total debt | $320.4M | $324.9M | $291.3M | $288.6M | $288.8M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Officer or director change
|
Aug 24, 2026 | Aug 19, 2026 |
| 10-Q | Quarterly report | Aug 7, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 7, 2026 | Aug 7, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
May 21, 2026 | May 21, 2026 |
All 1002 Ani Pharmaceuticals, Inc SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.